Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Phase 1 Completed 26 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment in the advanced disease setting.

Timeline

Start: 2006-12
Primary completion: 2011-09
Completion: 2011-09

Publications

Cardoso F, Canon JL, Amadori D, Aldrighetti D, Machiels JP, Bouko Y, Verkh L, Usari T, Kern KA, Giorgetti C, Dirix L. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast. 2012 Dec;21(6):716-23. doi: 10.1016/j.breast.2012.09.002. Epub 2012 Sep 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	—
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Trastuzumab	Monoclonal antibody	2 mg/kg	Intravenous
Background	Trastuzumab	Monoclonal antibody	6 mg/kg	Intravenous

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Summary

Timeline

Publications

Drugs

Indications